New Frontiers in the Treatment and
Management of Extensive Stage Small Cell Lung Cancer (SCLC): A
Closer Look at the Role of New and Emerging Immunotherapy
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2020 Fall
Managed Care Forum. If you participated in the live session, you are
not eligible for continuing education credits from this archive.
This activity is valid from November 1, 2020 to March 1, 2022
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
Small cell lung cancer (SCLC) is an aggressive form of the disease
that comprises 15% of all new lung cancer cases diagnosed each year
and this type of lung cancer tends to grow and spread faster than
non-small cell lung cancer (NSCLC). About 70% of people with SCLC
will have cancer that has already spread at the time they are
diagnosed. Outcomes for patients with SCLC are poor with a median
survival of less than 1 year. SCLC is a disease with limited
treatment options, presenting a strong unmet need, especially for
patients with metastatic disease that has progressed on or after
platinum-based therapy. Fortunately for patients with metastatic
SCLC, there are several therapy options, including immunotherapies,
that have been approved recently that have shown great promise in
their ability to improve clinical outcomes.
The treatment options for SCLC are based mainly on the stage of the
cancer, but other factors, such as a person’s overall health and
lung function are also important. Sometimes, combination options or
multiple therapies are used. More recently immunotherapies have
become available that give clinicians a new option with improved
safety and efficacy profiles in the fight against SCLC. Immune
checkpoint inhibitors have recently become available for patients
with extensive stage SCLC in many different treatment lines.
Additionally, new clinical trial data and novel options have become
available that shows the promise of immunotherapy in the first line
setting of extensive stage SCLC. The concept of tailoring therapies
based on clinical and molecular markers has transformed the
management of SCLC.
Upon completion of this
activity, participants will be able to:
Examine the clinical and economic
burden of small cell lung cancer (SCLC), including factors that
contribute to poor prognosis and increased costs
Review efficacy and safety data from
recent trials with immunotherapy in patients with extensive
stage SCLC in multiple lines of therapy
Assess biomarkers and techniques in
development to optimize selection of patients with extensive
stage SCLC for immunotherapy
Discuss strategies to manage
immune-related adverse events in patients with extensive stage
SCLC on immunotherapy regimens
Examine the managed care
considerations of new and emerging immunotherapies by exploring
where these agents fit in the evolving extensive stage SCLC
||Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine
University of Pennsylvania
serves as a consultant for AstraZeneca, Ayala, BMS,
Boehringer Ingleheim, Celgene, Clovis, Guardant Health,
Genentech, Inivata, Janssen, Merck, Regeneron, and
Takeda. He has received grants/research support from
AstraZeneca, Bayer, Carevive Systems, Clovis, Janssen,
Merck, Novartis, and Takeda. His presentation has been
peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue